Ischemic disorders of the heart can cause an irreversible loss of cardiomyocytes resulting in a substantial decrease of cardiac output. The therapy of choice is heart transplantation, a technique that is hampered by the low number of donor organs. In the present study, we describe the specific labeling, rapid but gentle purification and characterization of cardiomyocytes derived from mouse pluripotent embryonic stem ( 
Adult mammalian cardiomyocytes are terminally differentiated and have no or only limited regenerative capacity (1) . This is particularly limiting for a variety of heart disorders such as ischemic and dilated cardiomyopathies, where progressive heart failure can ultimately be treated only by transplantation. Due to the limited availability of organs, an alternative approach has been the isolation and implantation of different types of myocytes (2) and cardiomyocytes into the diseased myocardium of rodents (3) (4) (5) (6) . These studies demonstrated that transplanted cells could engraft and even form functional gap junctions with the host myocardium. In addition, revascularization as well as recovery from defective left ventricular function has been observed (5) . The lack of human cardiac cell lines, however, poses a serious limitation of this approach. Efforts to generate myocardial cell lines have focused largely on the targeted expression of oncogenes, either in cultured cardiomyocytes (7) or in the myocardium of transgenic animals (8, 9) . However, no established lines exhibiting the typical morphological and functional features of adult cardiomyocytes in particular after repeated passages have been reported. The establishment of a cardiac-specific cell line, i.e., of ventricular-like cardiomyocytes, would be a major step toward a cell-mediated replacement therapy.
Our and other groups have recently shown that cardiomyocytes derived from embryonic stem (ES) cells are a valid source for the generation of cardiomyocytes of different developmental stages. Pluripotent murine ES cells, derived from the inner cell mass of blastocysts (10) and adapted to permanent cell culture, can be induced to differ-entiate in vitro into a variety of cell lineages, i.e., cardiomyocytes (10, 11) skeletal (12) and smooth muscle (13) , neurons (14) , and endothelial cells (15) . In the case of the ES cell-derived cardiomyogenesis it has been unequivocally shown that at the terminally differentiated stage, all different cardiac phenotypes-sinus nodal-, pacemaker-, atrial-, and ventricular-like cells-can be detected (16) . In contrast to other primary or transgenic cardiac cell lines the ES cell system may provide a valid source for the generation of human cardiomyocytes, particularly after the recent establishment of human ES/EG cell lines (17, 18) as well as their differentiation (19) . However, the availability of ES cell-derived ventricular-like cardiomyocytes is limited by the fact that 1) only ϳ5% of all cells within EBs are cardiomyocytes, 2) all the different cardiac phenotypes are present, and 3) the isolation of these cardiomyocytes has been impossible so far (20) . To improve the selection of cardiomyocytes within EBs, an ␣-cardiac myosin heavy chain (MHC) promoter driving a neomycin selection gene was established (3) . After differentiation and selection using G418, exclusively cardiomyocytes survived. Because the ␣-MHC promoter is active in the entire adult heart, including atrial and pacemaker cells, all the different cardiac phenotypes are positively selected. Similarly, EGFP labeling of ES cell-derived cardiomyocytes driven by the human cardiac ␣-actin promoter stained all different phenotypes of cardiomyocytes (21) . In contrast, the myosin light chain-2v (MLC-2v) promoter is characterized by its ventricle specific expression (22) . Previously, we have shown that transgenic mice, in which the 2.1 kb MLC-2v promoter drives the luciferase reporter gene, display ventriclerestricted expression (23) and that this promoter driving the ␤-galactosidase reporter gene specifically stained ventricular cardiomyocytes in EBs (16) .
The aim of the present study was to establish ES cell lines from which ventricular-like cardiomyocytes could be identified, facilitating an easy and efficient isolation procedure. For this purpose transgenic ES cell lines were generated expressing the enhanced version of the green fluorescent protein (EGFP) under the transcriptional control of the CMV enh. / MLC-2v promoter. We demonstrate here that ventricle-specific expression occurs within several transgenic ES cell lines during early development. These EGFP-positive cells displayed morphological, histological, immunocytochemical, as well as electrophysiological features characteristic of ventricular-like cardiomyocytes. We further show reproducibly that large amounts of cardiomyocytes can be sorted using fluorescence-activated cell sorting (FACS).
MATERIALS AND METHODS

Transfection constructs
A 2.1 kb KpnI-EcoRI DNA fragment of the 5Ј upstream regulatory sequence of the rat cardiac MLC-2v gene (23) was subcloned in the pIC20H cloning vector. After subcloning of the MLC-2v promoter into pBluescript SKϩ (Sal I-EcoRI) (Stratagene, San Diego, Calif.), it was introduced in pEGFP-1 (Clontech, Palo Alto, Calif.) by EcoRI-XhoI digestion, resulting in the construct pMLC-EGFP. To enhance the MLC-2v promoter, the Ϫ590/91 bp fragment of the human cytomegalovirus immediate-early enhancer (CMV enh. ) (24) was generated by polymerase chain reaction (template: CMV-EGFP vector (Clontech), primers: forward FCMV: CTATGCGGC-CGCCGCTTCGAGCTCGCCCGACATTGATTATTGACTAGT and reverse RCMV: CTATGCGGCCGCATGGGGCGGAGTT-GTTACGACATTTTGGAAAGT) and inserted in pBLSK using NotI. After SacII-BamHI digestion, CMV enh. was subcloned clockwise into the same sites of pEGFP resulting in pCMV enh. -EGFP. The MLC-2v cassette was isolated from pMLC-EGFP by XbaI (blunt ended) -XhoI digestion and introduced in pCMV enh.
-EGFP BamHI (blunt ended) -XhoI. This vector was called pCMV enh. /MLC-EGFP (Fig. 1) ; 10 g Bgl II linearized vector was used for electroporation (240V/500 F) of 2.5 ϫ 10 7 ES cells.
Cell culture
The mouse embryonic stem cell line (GS-ES) (25) was provided by Dr. M. Aguet (ISREC, Lausanne, Switzerland). GS-ES cells are derived from the mouse strain Agouti 129/SV and were germline competent. In comparison to previously used D3 cells, they have a higher capacity to spontaneously differentiate to contracting cardiomyocytes. Transgenic ES cells were propagated in high glucose Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated ES qualified fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin, 1ϫ nonessential amino acids, 0.4 mg/ml GENETICIN (G418) (all reagents GIBCO BRL, Germany), and 0.1 mM ␤-mercaptoethanol (Sigma, Germany). They were kept undifferentiated on confluent feeder layers of mitomycin C-treated primary culture of murine embryonic fibroblasts and by addition of 1000 units/ml purified recombinant mouse leukemia inhibitory factor (ESGRO; Life Technologies, Inc., Grand Island, N.Y.). Cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 /95% air. Monolayers were passaged by trypsinization at confluence of 70 -80%. Figure 1 . Structure of the used EGFP transfection constructs. pMLC-EGFP contained the 2.1 kb MLC-2v promoter driving the EGFP marker gene, pCMV enh. /MLC-EGFP, the MLC-2v promoter plus the human CMV immediate-early enhancer element (CMV enh. ). pEGFP was a promoterless control construct. All constructs contained a CMV-neomycin cassette for positive selection in G418 (not shown).
In vitro differentiation was initiated essentially as described by Klug et al. (3) . Briefly, ES cells were harvested with 0.25% trypsin-EDTA and dissociated cells were transferred to bacteriological dishes at a density of 2 ϫ 10 5 ES cells/ml in ISCOVE's modified Eagle medium (Sigma) supplemented with 10% heat inactivated fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin, 1ϫ nonessential amino acids (all reagents Life Technologies, Inc.), and 450 M ␣-monothioglycerol (Sigma). After 3 days, EBs were transferred to new medium. At day 6, EBs with a similar size were plated onto gelatin-coated tissue culture dishes. The growth medium for the attached differentiation cultures was changed every other day.
For further characterization and purification of in vitro differentiated cardiomyocytes, the cells were processed according to a protocol for the isolation of primary rat neonatal cardiomyocytes (7) . Briefly, EBs were washed with phosphatebuffered saline (PBS) and digested by collagenase II (Worthington, N.J.) and pancreatin (Life Technologies, Inc.) in HEPES at pH 7.35 and 37°C for 2-4 h. Digestion was monitored microscopically.
Antibodies and immunofluorescence labeling
Embryoid body (EB) outgrowths (day 6ϩ25) or single cells prepared from day 6 ϩ 25 EBs and grown for another 2 days on gelatinized 12 mm glass coverslips (200,000 cells/ml) were rinsed with PBS fixed for 20 min at room temperature with 3.7% formaldehyde and neutralized with 50 mM glycine. The cells were permeabilized using 0.4% Triton X-100 in PBS and incubated with the primary antibody in a humidified chamber at 37°C for 2 h. After washing with 0.4% Triton X-100 and PBS, secondary Cy3-conjugated antibody was added and the specimen were incubated for 2 h at 37°C. Finally, the cells were washed and mounted with Mowiol 4 -88 (Calbiochem, Germany).
Monoclonal antibodies against skeletal and cardiac myosin (A4.1025) (26); atrial MHC (F88.12F8) (27) were obtained from Alexis Corp. (Grü nberg, Germany). TRITC-labeled phalloidin and the monoclonal antibodies recognizing sarcomeric ␣-actinin (EA-53) and fast skeletal myosin (My-32) were purchased from Sigma. Anti-troponin I antibody (4B7) has been described (28) .
FACS analysis
EB outgrowths (day 6ϩ25) were digested as mentioned above. 0.5 ϫ 10 6 cells were washed with PBS and fixed for 20 min in ice-cold 3.7% paraformaldehyde. The cells were permeabilized for 10 min using 0.4% Triton X-100 in cold PBS/5% bovine serum albumin (BSA) and incubated for 1 h with the primary antibody in a volume of 100 l PBS/5% BSA at 37°C. After washing twice with PBS/5% BSA, secondary Cy5-conjugated antibody (Dianova, Berlin, Germany) was added and the cells were incubated for 1 h at 37°C. Finally, the cells were washed in PBS and analyzed. Flow cytometric analysis was performed on a dual laser FACS Calibur (Becton Dickinson, Germany). A 530/30 nm bandpass filter was used to measure EGFP fluorescence intensity excited with the 488 nm line of an argon ion laser. CY5 fluorescence was excited separately by the 635 nm emission line of a laser diode and monitored with a 661/16 nm bandpass filter. Detector settings were adjusted with untransfected cells that were fixed, permeabilized, and stained as described above, except that the primary antibody was replaced by a corresponding isotype control antibody (MOPC-21, Sigma). Data of 50,000 cells were recorded using the CellQuest Acquisition software (Becton Dickinson).
Preparation of single cells and electrophysiology
For the patch-clamp experiments, whole EBs or beating areas of 20 -30 EBs (day 6ϩ15) were dissected and isolated by enzymatic dispersion, using collagenase B (Boehringer-Ingelheim, Germany) (29) . The solution used for the dissociation of the dissected areas was (in mmol/l): NaCl 120, KCl 5.4, MgSO 4 5, CaCl 2 0.03, Na pyruvate 5, glucose 20, taurine 20, HEPES 10, collagenase B 0.5-1 mg/ml, pH 6.9 (NaOH). The dissociated material was plated onto gelatin-coated glass coverslips and put into the incubator in 20% FCS containing DMEM medium. The glass coverslips containing the cells were placed into a temperature-controlled (37°C) recording chamber and perfused continuously with extracellular solution by gravity at a rate of ϳ1 ml/min. Substances were applied by exchanging the solution in the chamber; a 90% volume exchange was achieved within ϳ20 s. Patch pipettes (2-4 M⍀ resistance) were pulled from Clark (Electromedical Instruments, Reading, U.K.) borosilicate glass using a Zeitz puller (DMZ, Munich, Germany).
Spontaneously beating EGFP-positive cardiac cells were selected under a 40ϫ objective (Zeiss, Jena, Germany) using a Xenon excitation light source (Zeiss) and a FITC filter set. For the patch-clamp recordings, the whole-cell configuration of the patch-clamp technique was applied (29) . The cells were measured in the current-clamp mode using an Axopatch 200-A amplifier (Axon Instruments, Foster City, Calif.). Data were acquired at a sampling rate of 10 kHz, filtered at 1 kHz, stored on hard disk, and analyzed off-line using the ISO2 analysis software package (MFK, Frankfurt, Germany). Statistical analysis was performed using unpaired Student's t test, and a P value of Ͻ 0.05 was considered significant.
The 
Preparation of isolated cardiomyocytes from EBs
1 ϫ 10 8 collagenase II and pancreatin-treated EBs were resuspended in ES cell medium and purified by Percoll gradient centrifugation (7) . Using a bottom layer of 1.12 g/ml and a top layer of 1.06 g/ml, the cardiomyocytes migrated to the interface of both layers during centrifugation at 1300 g for 45 min. After removal of the top layer, cardiomyocytes were collected and washed twice in PBS. The final cell pellet was resuspended in ES cell medium. Cell sorting was performed on a FACStar PLUS cell sorter. EGFP was excited with the 488 nm line of an argon ion laser and recorded using a 530/30 nm bandpass filter. Sorting was based on the intensity of forward scattered light (FSC) and EGFP fluorescence intensity. The sort gate for EGFP-positive cells was established on the basis of the FSC and EGFP intensity of untransfected cells. EGFP-positive cells were sorted directly into culture medium containing tissue flasks for further cell culture or sorted into glass tubes containing culture medium and reanalyzed to estimate sort purity. WinMDI Software (Joe Trotter, Scripps Institute, San Diego, Calif.) was used for data presentation and statistical evaluation of the defined cell populations.
RESULTS
Identification of the EGFP-positive ES cell clones
The structure of the three electroporation constructs is depicted in Fig. 1 . 10 -20 ES cell clones of each construct were selected, amplified, and differentiated. In the case of the MLC-2v promoter construct, three positive clones were identified (clones #6, #10 and #20), but the number of EGFP-positive cells per beating area at all developmental stages was low (Յ 20) (Fig. 2 and Table 1 ). In contrast, the number of EGFP-positive cells per beating area in CMV enh. / MLC-EGFP-positive EBs was increased (Fig. 2) . For this construct, nine positive clones were identified with four clones (#15, #18, #22, and #27) displaying a high number of green fluorescent cells (Ͼ20) within the spontaneously beating areas of EBs ( Table  1 ). The remaining five CMV enh. /MLC-EGFP clones showed similar results as the MLC-EGFP clones. As expected, in the negative control with the promoterless EGFP construct no green fluorescent cells were observed despite the high number of beating areas within these EBs (data not shown).
Characterization of the in vitro differentiation of ES cell-derived EGFP-positive clones
At different times, EBs were analyzed for beating and content of EGFP-positive cells. Three positive CM-V enh. /MLC-EGFP clones (#18, #22, and #27), all showing more than 20 green fluorescent cells per beating area, one MLC-EGFP clone (#20), and one untransfected control were investigated by light microscopy (Fig. 3A) . All clones analyzed showed a similar developmental pattern with first contracting cells in the EB outgrowths reproducibly appearing at day 6 ϩ 6. At day 6 ϩ 13, ϳ20% of the total EB outgrowth was beating (Fig. 3A) , whereby 85 Ϯ 5% of all EBs displayed contracting areas (data not shown). At later time points the number of beating areas within EBs decreased and at day 6 ϩ 30 almost no beating areas were observed (Fig. 3A) .
Analysis by fluorescence microscopy ( Fig. 3B ) and flow cytometry (Fig. 3C) of differentiating CMV enh. / MLC-EGFP transfected EBs revealed first EGFP-positive cells 2 days after the onset of spontaneous contractions (day 6 ϩ 8). Subsequently, the number of EGFP-positive cells increased up to day 6 ϩ 25 ( Fig. 3B) . The maximum of fluorescence intensity was reached at day 6 ϩ 35 ( Fig. 3C) . At later time points, a slight drop in both the intensity and the number of EGFP-positive cells was noticed. Among the CMV enh. /MLC-EGFP clones, #27 showed the highest amount of fluorescent cells and the strongest intensity of fluorescence, and was therefore chosen for further analysis. The fluorescence intensity of MLC-EGFP-positive cells (clone #20) and cells of the untransfected control were below detection level (Fig. 3C) .
Specificity of the EGFP expression in ES cellderived cardiomyocytes
The cardiac nature of the EGFP expressing cells within the EB (clone #27) was proven with antibody staining specific for fast skeletal myosin (My-32). FACS analysis of enzymatically dispersed single cells showed that only a small population of EGFP negative skeletal muscle cells was present in the EB (0.06%) (Fig. 4A) . No fluorescent My-32-positive skeletal myocytes could be detected. Staining with antibodies against either ␣-actinin (Fig. 4B ) or myosin (data not shown) demonstrated that almost all EGFP-positive cells (91%) stain positive with either antibody. However, only 0.4% out of total 1.52% sarcomeric cells were green fluorescent (27%) (Fig.  4B) . Staining with an antibody specific for human atrial myocytes resulted in only 0.01% EGFP doublepositive cells (Fig. 4C) . No EGFP staining was detectable in the IgG control experiment (Fig. 4D) . Similarly, immunohistochemistry with EBs stained for myosin showed that only a subpopulation of cells within a distinct myofibrillar structure was positive for EGFP (Fig. 5A, B) . EBs generated from less than 2 ϫ 10 5 ES cells favored skeletal muscle differentiation, which was detected preferentially at the periphery of the EB with no skeletal myosin staining of EGFP-positive cells (data not shown). Striations by sarcomeric structures could be detected with antibodies against ␣-actinin (Fig. 5C, D) and troponin I (data not shown) in EGFP-positive as well as EGFPnegative cells. Antibody staining for human atrial myosin detected a small population of EGFP-positive cells (Fig. 5E, F) .
Electrophysiological and pharmacological characterization of EGFP-positive cardiomyocytes
To examine the electrophysiological properties of ES cell-derived cardiomyocytes, patch-clamp recordings were performed on spontaneously contracting isolated cardiomyocytes. EBs of CMV enh. /MLC-EGFP transfected ES cells were harvested at day 6 ϩ 15.
The ventricular specificity of CMV enh. /MLC-EGFP labeling is summarized in Fig. 6A . Thirteen of 16 EGFP-positive cells (82%) displayed typical ventricular-like action potentials (AP) with a negative membrane potential of Ϫ68.6 Ϯ 2.8 mV, an AP duration (APD) of 118.3 Ϯ 15.2 ms, an overshoot of 34.3 Ϯ 3.9 mV, and the clearly pronounced plateau phase indi- cating the long lasting Ca 2ϩ influx through L-type Ca 2ϩ channels (Fig. 6B) (31) . Furthermore, these 13 cells revealed prolongation of APD in the presence of the ␤-adrenergic agonist isoprenaline (Iso, 0.1 M), which is known to prolong APD at the late developmental stage due to stimulation of L-type Ca 2ϩ -channels (31) . Incubation with the muscarinic agonist carbachol (CCh, 1 M), which has a pronounced negative chronotropic effect on the spontaneous electrical activity in early cells, did not result in any effect on APD and the membrane potential of EGFP-positive cells as can be expected for ventricular-like cardiomyocytes (34) . 12% of EGFP-positive cells (nϭ2) showed atrial-like membrane potentials whereas 6% could be classified as early-type cardiomyocytes (nϭ1) (Fig. 6A) . In contrast, EGFP negative cells revealed a strong negative chronotropic response on CCh application without concomitant hyperpolarization (nϭ5) (data not shown). In accordance with earlier studies, no toxicity associated with the expression of EGFP could be detected (21) .
Purification of EGFP-positive ventricular-like cardiomyocytes
To achieve a pure fraction of ventricular-like cardiomyocytes, we performed a dual strategy including Percoll gradient density centrifugation followed by FACS. EB outgrowths generated from 1 ϫ 10 6 ES cells were digested at day 6 ϩ 25. 1 ϫ 10 8 unpurified differentiated cells containing ϳ0.2% green fluorescent particles ( 2ϫ10 5 ) (Fig. 7A) were loaded on a Percoll gradient, resulting in a three-to fivefold enrichment of EGFP-positive cells (Fig. 7B) . Subsequent FACS yielded in a 97% pure fraction of 5 ϫ 10 4 EGFP-positive cells (Fig. 7C) . Adherent cells started to contract again and demonstrated an intact sarcomeric structure (Fig. 8A-D) .
DISCUSSION
We here present a novel approach for the labeling and rapid purification of ventricular-like ES cellderived cardiomyocytes. With the help of the ventricle-specific CMV enh. /MLC-2v promoter driving an EGFP reporter gene, a specific staining of the ventricular-like subpopulation was achieved. The combination of Percoll purification and FACS sorting allowed a fast and reproducible enrichment of the EGFP-positive cell population containing as many as Figure 6 . A) Patch-clamp analysis of CMV enh. /MLC-EGFP transfected green fluorescent cardiomyocytes. EBs were grown to day 6 ϩ 15 before single isolated cardiomyocytes (GS, nϭ16) were characterized by their electrophysiological properties (action potentials and ion currents) using the patch-clamp technique. Based on the type of action potential, recorded cells were classified as ventricle-like, atrial-like, early, atrio-ventricular-like, and Purkinje-like. B) Hormonal modulation of the spontaneous electrical activity of EGFPpositive ES cell-derived cardiomyocytes using current clamp recordings: Two representative EGFP-positive cells show ventricular-like action potentials: a relatively long action potential duration plateau phase, negative maximal diastolic potential, and a large overshoot. These EGFP-positive cells were insensitive to treatment with the muscarinic agonist, carbachol (CCh). In contrast, the ␤-adrenergic agonist isoprenaline prolonged the action potential duration of EGFP-positive cells and evoked a positive chronotropic response, which was reversed by wash out. 6 undifferentiated stem cells. The 2.1 kb MLC-2v promoter was chosen because MLC-2v mRNA is specifically found during heart tube formation at day 8 p.c. (32) . Within the adult mammalian heart, it is later expressed almost exclusively in the ventricles (23) . Similarly, in the EB cell system, MLC-2v mRNA was detected with the onset of spontaneous contractility (33) . In contrast to the strong activity of the MLC-2v promoter in transgenic mice (23) and in the adenoviral system (34), transfected EBs revealed poor expression levels of the MLC-2v-driven EGFP-marker gene. This has also been observed by other groups (personal communications). We therefore included the CMV enhancer element (25) , which in transgenic animal experiments was able to increase MLC-2v expression levels without significantly altering its tissue specificity (publication in preparation).
To our knowledge this is the first time that the specific labeling, purification, and characterization of in vitro differentiated ventricular-like cardiomyocytes are shown. In similar experiments Klug et al. (3) and, more recently, Kolossov et al. (21) achieved selection and characterization of EB derived cardiomyocytes. The usage of these cardiomyocytes for cell transplantation into the heart is limited by the fact that the respective promoters, ␣-MHC (3) and ␣-actin (21) do not possess specificity distinguishing between different types of cardiomyocytes. Using FACS analysis, 1.5% of the total in vitro differentiated cell population and ϳ91% of EGFP-fluorescent cells show myogenic ␣-actinin. Since there is no evidence for the presence of skeletal muscle cells in our EB preparations (0.06% skeletal myosin-positive cells), we conclude that all ␣-actinin-positive cells are of a cardiac phenotype, between 25 to 30% of those comprising an EGFP-positive staining pattern. This proportion fits well with earlier observations showing that ϳ25% of cardiomyocytes in the EB environment show ventricular-like characteristics (7) . It is worth mentioning that EGFP-positive cells are not distributed equally in between different beating areas but concentrate on some areas (up to 90%), whereas other contracting populations are almost devoid of any EGFP activity. During all experiments, we had no indication of a toxic effect of the EGFP expression. Cultivation for more than 100 days did not reduce the number of EGFP-positive cells in the EB. Electrophysiological measurements suggest that the EGFP-positive cardiomyocyte fraction within the EB contained 82% ventricular-like, 12% atrial-like, and 6% early cardiomyocytes at developmental day 6 ϩ 15. Using FACS analysis, virtually no atrial EGFPpositive cardiomyocytes could be detected (0.01%). The discrepancy revealed between the proportions of EGFP-positive atrial-like cardiomyocytes estimated by electrophysiology, immunohistochemistry, and FACS may be due to dedifferentiation processes resulting from the different handling of the analyzed cardiomyocytes. For FACS analysis, the cells were processed immediately after treatment of the EBs with collagenase. In contrast, for immunohistochemistry with single cells (Fig. 5C-F) or for electrophysiological measurements, as well as for selection procedures using antibiotics (3), the cells were plated again on culture dishes for an extended period of time. During this period of time the gene expression pattern alters and the morphology of the cardiomyocytes changed from a spindle-shaped, triangular to a flat polymorphic-shaped form with multiple pseudopodia-like processes. This observation is a first indication of a starting dedifferentiation process, an observation commonly seen in primary cultures of cardiomyocytes (36, 37) . Dedifferentiation does not take place in EGFP-positive cardiomyocytes as long as they are kept in their natural environment of the growing 3-dimensional EB. Moreover, it might be speculated that the few electrophysiologically atrial- Neo-resistant cardiomyocytes and Neo-sensitive noncardiomyogenic cells, a high number of Neo expressing cells gets lost with medium changes and therefore clumps of detached cells had to be collected and plated again (M. Müller, data not shown), a procedure that is inefficient and time consuming. The cellular transplantation of fetal, neonatal and adult cardiomyocytes, skeletal muscle cells, satellite cells, and cardiac tumor cells into the myocardium of various species such as mouse, rat, and dog is well established (38, 39) . Klug et al. has shown that ES cell derived cardiomyocytes can generate cardiac grafts when transplanted into dystrophic recipient mice (3). With our EGFP-based purification method, we get enough pure cardiomyocytes to perform transplantations into the murine heart (Ն 1ϫ10 4 ). To achieve cellular transplantation in larger animals and humans, a higher number of cardiomyocytes will be required (Ն 10 6 cells) (40) . Indeed, we have recently shown that treatment of EBs with retinoic acid is advantageous (16) . Another possibility to increase the quantity of differentiating cardiomyocytes might be the overexpression of GATA transcription factors in ES cells, which has been shown to lead to a fourfold increase in cardiomyocyte differentiation (41) .
The availability of human ES/EG cells (17) (18) (19) ) and the possibility of differentiating cardiomyocytes from human ES cells (19) , bone marrow stromal cells (42) , as well as the newly described nuclear transfer technology (43) offer an enormous potential for cell mediated gene therapy. However, most of these in vitro differentiation methods give rise to more than 200 different types of cells, and therefore the strength of these discoveries can only be used if a distinct cellular subset can be isolated. The availability of purified human cardiomyocytes will allow the discovery of new growth factors, the evaluation of drugs, and toxicologic in vitro studies. Our study describes the potential to label and rapidly purify specifically ventricle-like cardiomyocytes, which in the near future may open new avenues in the treatment of congestive heart failure. This work was funded by BMBF grant 01KV9560. M.M. was supported by a Swiss National Science Foundation grant. We are grateful to Tanja Ubben for her excellent technical assistance. We thank Dr. Michel LeHir for his assistance in immunhistologie. We are further grateful to Dr. F. Boess for carefully reading the manuscript.
